Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunobinop in Alcohol Use Disorder
NCT06545916Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2024
- Primary completion
- May 2026
- Countries
- 2
- Sponsor
- Knoa Pharma
- Modality
- Small Molecules
- Drugs
- sunobinop
- Conditions
- alcohol use disorder (AUD)
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Sunobinop with Placebo (2 arms). Primary endpoint: Percent heavy drinking days at Day 57. Started Oct 2024; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Sunobinop
Sunobinop 1 tablet orally at bedtime
Placebo
Placebo 1 tablet orally at bedtime
03
Who it enrols
Adults ≥18 years with moderate to severe alcohol use disorder seeking treatment, with at least 4 heavy drinking days per week in the 4 weeks prior to baseline, excluding those with other moderate/severe substance use disorders (except nicotine).
04
Endpoints
Primary
Percent heavy drinking days
Secondary
Number of standard unit drinks
Percent of drinking days
Beyond the preview
Go deeper on NCT06545916.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545916.